GAIN THERAPEUTICS INC (GANX) Stock Balance Sheet
NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 5.64M | 5.03M | 2.91M | 3.26M | N/A | |||
| Cash Equivalents | 4.75M | 6.77M | 4.40M | 33.62M | 7.49M | |||
| Marketable Securities | N/A | 5.00M | 12.83M | 33.62M | N/A | |||
| Receivables | 765.80K | 242.60K | 190.00K | 200.00K | 70.00K | |||
| Other Current Assets | 450.90K | 741.60K | 760.00K | 650.00K | 1.43M | |||
| Total Current Assets | 11.60M | 17.78M | 21.09M | 37.72M | 8.99M | |||
| Non-Current Assets | ||||||||
| PPE Net | 323.30K | 778.60K | 1.02M | 1.21M | 550.00K | |||
| Investments And Advances | N/A | 0.00 | 1.94M | N/A | N/A | |||
| Intangibles | 134.30K | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 63.80K | 51.90K | 50.00K | 50.00K | 60.00K | |||
| Total Non-Current Assets | 521.40K | 830.40K | 3.01M | 1.27M | 610.00K | |||
| TOTAL ASSETS | 12.12M | 18.61M | 24.10M | 38.99M | 9.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 110.20K | 118.80K | 110.00K | 100.00K | 20.00K | |||
| Accrued Expenses | 2.35M | 1.97M | 1.97M | 1.37M | 800.00K | |||
| Accounts Payable | 946.30K | 1.32M | 1.63M | 560.00K | 960.00K | |||
| Other Current Liabilities | 500.00K | 1.54M | 420.00K | 520.00K | 330.00K | |||
| Total Current Liabilities | 3.91M | 4.95M | 4.13M | 2.55M | 2.11M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 328.30K | 449.10K | 500.00K | 590.00K | 720.00K | |||
| Other Non-Current Liabilities | 544.70K | 632.10K | 600.00K | 1.02M | 570.00K | |||
| Total Non-Current Liabilities | 873.00K | 1.08M | 1.09M | 1.62M | 1.29M | |||
| TOTAL LIABILITIES | 4.78M | 6.03M | 5.22M | 4.17M | 3.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -81.19M | -60.78M | -38.52M | -20.93M | -7.03M | |||
| Additional Paid In Capital | 88.78M | 73.11M | 57.36M | 55.83M | 13.39M | |||
| Common Shares | 2.70K | 1.60K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -247.60K | 247.20K | 40.00K | -90.00K | -150.00K | |||
| Shares Outstanding | 27.13M | 16.21M | 11.88M | 11.88M | 11.33M | |||
| Tangible Book Value per Share | 0.27 | 0.78 | 1.59 | 2.93 | 0.55 | |||
| Total Shareholders' Equity | 7.34M | 12.58M | 18.88M | 34.82M | 6.20M | |||
| TOTAL LIABILITIES AND EQUITY | 12.12M | 18.61M | 24.10M | 38.99M | 9.60M | |||
| Statistics | ||||||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.02 | 0.12 | |||
| Current Ratio | 2.97 | 3.59 | 5.11 | 14.79 | 4.26 | |||
| Return On Assets (ROA) | -168.36% | -119.66% | -72.99% | -35.62% | -37.29% | |||
| Return On Equity (ROE) | -278.10% | -177.03% | -93.17% | -39.89% | -57.74% | |||
All data in USD , ROIC based on taxRate of 0.21